NEXIMMUNE, INC.

Analyst Reco. NexImmune, Inc.

Equities

NEXI

US65344D2080

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-17 EDT			5-day change	1st Jan Change
2.95 ^USD	0.00%		+8.06%	+32.88%

05-20	NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-17	North American Morning Briefing : Stock Futures -2-	DJ

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Raymond James Downgrades NexImmune to Market Perform From Outperform	22-11-15	MT
Raymond James Adjusts NexImmune's Price Target to $3 from $12, Maintains Outperform Rating	22-08-16	MT
Barclays Cuts Price Target on NexImmune to $2 From $7, Keeps Overweight Rating	22-08-16	MT
Cantor Fitzgerald Adjusts Price Target for NexImmune to $4 From $35, Maintains Overweight	22-06-30	MT
BTIG Starts NexImmune at Buy With $5 Price Target	22-06-01	MT
Barclays Raises NexImmune's Price Target to $7 From $4, Maintains Overweight Rating	22-04-01	MT
Raymond James Adjusts NexImmune's Price Target to $13 from $21, Maintains Outperform Rating	22-02-22	MT
Raymond James Adjusts Price Target on NexImmune to $21 From $30, Keeps Outperform Rating	21-11-15	MT
NEXIMMUNE : Raymond James Initiates Coverage on NexImmune With Outperform Rating, $30 Price Target	21-04-01	MT
NEXIMMUNE : Cantor Fitzgerald Starts NexImmune at Overweight With $35 Price Target	21-03-09	MT
NEXIMMUNE : Barclays Starts NexImmune at Overweight With $35 Price Target	21-03-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer